trending Market Intelligence /marketintelligence/en/news-insights/trending/tB8dgoRxLrZPSvM71SD2UQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Alexion, Zealand Pharma sign deal to discover peptide therapies

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


Alexion, Zealand Pharma sign deal to discover peptide therapies

Alexion Pharmaceuticals Inc. and Zealand Pharma A/S will collaborate to discover and develop peptide-based therapies that target diseases related to the body's complement system.

Under the agreement, Boston-based Alexion will pay $25 million up front and make a $15 million equity investment in Denmark-based Zealand.

Alexion will have exclusive worldwide licenses and commercial rights for up to four targets within the complement pathway. The complement system is a part of the immune system which enhances the ability of antibodies to fight damaged cells. The system is thought to play a role in many diseases.

Zealand Pharma will lead discovery and research activities in the preclinical stage, while Alexion will oversee development from filing the investigational new drug application and phase 1 trials.

Zealand Pharma may receive up to $115 million in development-related milestones, and up to $495 million in sales-related milestones and potential royalty for the lead target.

Alexion has the option to select the remaining three target therapies for $15 million each, plus potential development and sales-related milestone payments along with royalties at a lower price than the lead candidate.